Investment analysts at JonesTrading assumed coverage on shares of Adlai Nortye (NASDAQ:ANL – Get Free Report) in a research note issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $22.00 price target on the stock. JonesTrading’s target price would suggest a potential upside of 58.73% from the company’s current price.
A number of other brokerages have also recently commented on ANL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a report on Wednesday, January 21st. Leerink Partners initiated coverage on Adlai Nortye in a report on Friday, March 20th. They issued an “outperform” rating and a $23.00 target price on the stock. Wall Street Zen raised Adlai Nortye to a “hold” rating in a report on Saturday, March 7th. Finally, HC Wainwright raised their target price on Adlai Nortye from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, April 20th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $21.67.
View Our Latest Stock Report on Adlai Nortye
Adlai Nortye Price Performance
Institutional Investors Weigh In On Adlai Nortye
An institutional investor recently raised its position in Adlai Nortye stock. SmartHarvest Portfolios LLC boosted its holdings in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Free Report) by 8.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,367 shares of the company’s stock after buying an additional 1,279 shares during the period. SmartHarvest Portfolios LLC’s holdings in Adlai Nortye were worth $113,000 as of its most recent SEC filing. 35.21% of the stock is owned by institutional investors.
Adlai Nortye Company Profile
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Read More
- Five stocks we like better than Adlai Nortye
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
- Cisco’s Vertical Rally May Still Be in the Early Innings
- Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
